Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,957 total articles
SurgePays, Inc., a fintech and wireless point of sale company serving subprime and underserved consumers, announced it will report its financial results for Q4 and full year 2025 on April 14, 2026, with a scheduled conference call and webcast for investors.
Aware, Inc. announced its Intelligent Liveness biometric authentication system performed exceptionally well in the U.S. Department of Homeland Security's Remote Identity Validation Rally. The system achieved zero successful attacks in the active liveness test, ranked highly for user satisfaction and speed, demonstrating robust security without sacr…
Riverview Bancorp declared a quarterly cash dividend of $0.02 per share, unchanged from the previous quarter. The dividend will be paid on April 24, 2026, to shareholders of record as of April 13, 2026. The company operates as a regional community bank with assets of $1.51 billion and a focus on commercial, business, and retail clients primarily in…
Brookfield Business Corporation has filed its 2025 annual report with the SEC and Canadian securities authorities, including audited financial statements. The company finalized a corporate simplification by exchanging various partnership units for newly issued Class A shares, which will begin trading on the NYSE and TSX under the ticker BBUC starti…
Ellomay Capital Ltd. has published the financial statements of Dorad Energy Ltd. for the year ended December 31, 2025. Ellomay holds an indirect 16.9% stake in Dorad through Ellomay Luzon Energy. Dorad reported revenues of approximately NIS 2.65 billion and an operating profit of NIS 385 million for 2025. The results were impacted by seasonal elect…
Data Storage Corporation announced the postponement of its fiscal year 2025 investor conference call to allow more time to complete its year-end audit. The audit complexity stems from significant transactions including the sale of its CloudFirst subsidiary, warrant settlements, and a tender offer. A new date for the earnings call will be announced …
HeartCore Enterprises, Inc., a Tokyo-based IPO consulting services company listed on Nasdaq (HTCR), announced its full year 2025 results. The company reported revenues of $9.0 million, gross profit of $3.2 million, and net income of $5.5 million compared to a net loss last year. The positive net income was primarily due to gains from the divestitur…
Cognition Therapeutics announced progress in developing their lead candidate, Zervimesine (CT1812), for neurodegenerative diseases. Positive Phase 2 SHIMMER trial results support advancing the drug to late-stage trials for dementia with Lewy bodies (DLB) psychosis. The ongoing fully funded Phase 2 START trial in mild cognitive impairment and early …
Tarsus Pharmaceuticals has dosed the first participant in its Phase 2 Calliope trial evaluating TP-05 (lotilaner), an investigational oral systemic therapy aimed at preventing Lyme disease by killing infected ticks before transmission. The randomized, placebo-controlled trial will enroll approximately 700 adults at risk across endemic U.S. regions,…
Bel Fuse Inc. announced a strategic organizational realignment from a product-centric to an end-market-centric structure, consolidating its business units into two focused divisions: Aerospace, Defense & Rugged Solutions and Industrial Technology & Data Solutions. This restructuring is intended to sharpen market focus, accelerate innovation, and en…
BIO-key International announced its 2025 financial results showing $6.1M revenue with a 12% decline from 2024 due to strategic shifts in the EMEA region. The company improved its cash position to $2.7M and expects solid revenue growth and improved profitability in 2026, driven by increased demand in foreign military, defense, financial sectors, and…
Duos Technologies Group, Inc. announced record revenues for 2025, achieving $27 million representing over 270% growth year-over-year. The company accelerated its transition to modular edge data centers and high-density AI infrastructure, including launching GPU-as-a-Service and expanding hosting and technology solutions. Supported by strong capital…
LanzaTech Global, Inc. announced its fourth quarter and fiscal year 2025 financial results, showing substantial revenue increases to $55.8 million in 2025 from $49.6 million in 2024, driven by higher licensing revenue and CarbonSmart product sales. The company achieved a reduced net loss of $49.0 million in 2025 versus $137.7 million in 2024, owing…
PolyPid Ltd. has begun submitting its New Drug Application for D-PLEX100 to the FDA under a rolling review process, targeting approval by Q2 2026. The lead product, designed to prevent surgical site infections after colorectal surgery, demonstrated significant efficacy in Phase 3 trials and has received FDA Breakthrough Therapy Designation. The com…
GoHealth, Inc. announced its full year 2025 financial results, emphasizing a strategic pullback in Medicare Advantage enrollments due to market conditions. The company prioritized consumer fit, renewal economics, cash discipline, and continued leadership in specialized needs plans (SNPs). GoHealth invested in AI and technology to improve efficiency…
BlockchAIn Digital Infrastructure, Inc. (NYSE American: AIB) completed its business combination and began public trading in March 2026. The company operates a 40 MW data center and is advancing its growth plans with over $500 million in potential contract value from letters of intent. BlockchAIn focuses on AI and HPC digital infrastructure developm…
Nuwellis, Inc. announced that its pediatric category has become its largest and fastest-growing revenue segment, comprising approximately 50% of total U.S. revenue in 2025. The Aquadex therapy platform's adoption has expanded to 47 pediatric centers, including six of the top 10 children's hospitals, reflecting strong clinical acceptance and strateg…
Skeena Resources Limited announces a proposed $750 million offering of Senior Secured Notes due 2031 to refinance former project financing and fund a partial buyback of its existing $200 million gold stream. The transaction aims to improve operating margins, increase exposure to gold prices, and enhance project economics for the Eskay Creek Gold-Si…
Edible Garden AG Incorporated reported its 2025 financial results, highlighting strategic expansion beyond controlled environment agriculture into higher-margin ready-to-drink (RTD) and shelf-stable consumer packaged goods. The company increased its retail footprint to nearly 6,000 locations, including major partners like Kroger and Amazon, and is …
Kartoon Studios announced a 21% increase in total revenue to $39.4 million for 2025, driven largely by a 50% growth in animation production services. The company's operating loss improved by 24%, reflecting cost discipline and a shift toward higher-margin franchise monetization. Kartoon Studios is scaling its distribution platforms with record subs…
Foremost Clean Energy Ltd. completed a bought deal private placement raising aggregate gross proceeds of C$5.7 million by issuing flow-through units to support exploration of its uranium and lithium properties in Canada. The capital will be used to incur qualifying Canadian exploration expenses on the company's mineral properties in Saskatchewan an…
LifeMD, Inc. announced the launch of Novo Nordisk’s Wegovy® telehealth subscription program available through its virtual primary care platform, offering significant cost savings and improving patient access and adherence to branded GLP-1 obesity therapy. This initiative deepens LifeMD's collaboration with Novo Nordisk and integrates subscription p…
Cadrenal Therapeutics reported strong fourth quarter and full-year 2025 results, highlighted by positive Phase 2 clinical data for its lead drug CAD-1005 treating heparin-induced thrombocytopenia (HIT). The company completed an End-of-Phase 2 meeting with the FDA, clarifying the regulatory strategy for its Phase 3 pivotal trial. CAD-1005 showed a s…
Pelthos Therapeutics announced the dosing of the first patient in a Phase 1b/2a clinical trial evaluating CT2000, an investigational NaV1.7 inhibitor eye drop formulation, as a treatment for acute and chronic ocular pain associated with dry eye disease. The trial will assess safety and efficacy with results expected by the end of 2026. Positive pre…
Dycom Industries appoints industry veteran Bo Gresham as its first Chief Revenue Officer to lead revenue growth and strategic market expansion amid a multi-year boom in digital infrastructure and fiber deployments. With nearly 30 years of experience, Gresham's promotion reflects Dycom's commitment to internal talent development and positions the co…
